Rishab Kumar

Articles by Rishab Kumar

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia

ByJalpa A. Doshi, PhD,Pengxiang Li, PhD,Hairong Huo, PhD, MS,Amy R. Pettit, PhD,Rishab Kumar,Brendan M. Weiss, MD,Scott F. Huntington, MD, MPH

March 18th 2016

A Medicare claims analysis of patients newly diagnosed with chronic myeloid leukemia revealed that high cost sharing was associated with reduced and/or delayed tyrosine kinase inhibitor initiation under Part D.

Latest Updated Articles

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia
March 18th 2016

Rishab Kumar

Articles by Rishab Kumar

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia

Latest Updated Articles

Trending on AJMC

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer

Orexin Agonist Shows Promise for Treating Narcolepsy, Hypersomnia: Richard Bogan, MD

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs